Thomas Lynch is a business development professional and scientist with over 25 years of combined sales and laboratory experience. He currently leads the commercial activities for Aldevron’s Protein Business Unit and is responsible for the Gene Editing Platform & CRISPR portfolio of products. Prior to Aldevron, his research focused on the structural analysis of protein:nucleic acid complexes and biomolecular recognition. Dr. Lynch holds a Ph.D. in biochemistry from the University of Illinois and B.S. in biochemistry from the University of Minnesota.